OPEN END TURBO BULL OPTIONSSCHEIN - ASTRAZENECA | Real-time Bid/Ask 16:35:31 02/05/2024 BST | ||
| 5.66 EUR / 5.69 EUR | +2.25% |
|
| 1 month | +37.04% | ||
| 3 months | +41.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 5.71 | +2.88% | 0 |
| 30/04/24 | 5.55 | +0.18% | 0 |
| 29/04/24 | 5.54 | -0.54% | 0 |
| 26/04/24 | 5.57 | +0.72% | 0 |
| 25/04/24 | 5.53 | +16.42% | 0 |
Delayed Quote Börse Stuttgart
Last update May 02, 2024 at 01:53 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR6WZE |
| ISIN | DE000HR6WZE1 |
| Date issued | 16/04/2021 |
| Strike | 7,268 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.12 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.19 € |
|---|---|
| Lowest since issue | 1.04 € |
| Spread | 0.01 € |
| Spread % | 0.17% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
152
USD
Average target price
164.3
USD
Spread / Average Target
+8.09%
- Stock Market
- Certificates
- Certificat
